Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984667 · ClinicalTrials.gov registry record
C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
A clinical trial of Brain Tumor and Mild Neurocognitive Disorder, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT05984667 is a study of Brain Tumor and Mild Neurocognitive Disorder that has completed, run by Virginia Commonwealth University. The registered enrollment target is 32 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05984667, a study of Brain Tumor and Mild Neurocognitive Disorder, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of participants will undergo rs-fMRI both pre- and post-C-SMART to test feasibility of advanced functional imaging in this population.
Conditions Studied
Interventions
- BEHAVIORAL C-SMART
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2025-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05984667
The ClinicalTrials.gov registry entry for NCT05984667 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which C-SMART is the first listed.
NCT05984667 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05984667 about?
NCT05984667 is a clinical study titled "C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors". The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of participants will undergo rs-fMRI both pre- and post-C-SMART to test feasibil...
What is the current status of trial NCT05984667?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2023-09-15. Estimated completion is 2025-07-23.
What conditions does trial NCT05984667 study?
This clinical trial studies the following conditions: Brain Tumor, Mild Neurocognitive Disorder, Glioma, Mixed.
What interventions are being tested in trial NCT05984667?
The interventions under investigation include: C-SMART (BEHAVIORAL).
Who is sponsoring clinical trial NCT05984667?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05984667 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.